AMAshleigh McGirr

Ashleigh McGirr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ashleigh McGirr has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pruritus and health-related quality of life in chronic liver disease: a longitudinal, survey-based cohort study

    by Usha Gungabissoon, Jake Hunnicutt, Eleanor J McDermott, Andrew Lovley, Monica S Frazer, Kaitlin M LaGasse, Mark Kosinski, Kristen L McCausland, Ashleigh McGirr, Helen T Smith, et al.

    Objective: Cholestatic pruritus is commonly reported in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC); however, information on pruritus in other chronic liver diseases (CLDs) is limited. This survey-based cohort study characterised the severity, persistence and impact of pruritus in PBC, PSC, chronic hepatitis B or C virus infection (HBV/HCV), drug-induced liver injury, autoimmune hepatitis (AIH) and metabolic dysfunction-associated steatohepatitis (MASH). Here, we focus on groups that recruited the most participants: PSC, MASH and HCV. Results are presented in the context of PBC. Methods: Adults with a CLD of interest from the USA, the UK, Canada and Germany were screened for the presence of pruritus via the worst-itch numerical rating scale (WI-NRS, 3-month recall) between January 2021 and January 2022. Enrolled participants (single liver disease, non-transplant recipients) self-reporting pruritus with no extrahepatic causes in the past 3 months (WI-NRS≥1) were eligible for further health-related quality-of-life (HRQoL) assessments, including WI-NRS (2-week recall), 5-dimensional itch scale and version two of the 36-Item Short-Form Health Survey. Questionnaires were administered at baseline (month 0), month 3 and month 6. Results: Of 717 screened participants, 40.4% (AIH)–72.7% (HCV) reported any pruritus. Of 403 eligible participants, 357 were enrolled. Time since onset of pruritus to enrolment ranged from 28.0 (MASH) to 77.5 months (PBC). Baseline WI-NRS scores ranged from 3.8 (MASH) to 5.1 (PSC). The most selected terms used to describe pruritus across all CLDs were ‘deep itch’ and ‘urgent itch’ (range: 53.7% (HCV)–77.0% (PSC)). Participants with more severe pruritus had worse HRQoL. Intimate relationships, emotional well-being and ability to concentrate were negatively impacted by pruritus. Pruritus persisted over the 6-month study period across all CLDs. Conclusion: Our study highlights the burden of pruritus experienced by participants across CLDs, highlighting a need to improve symptom recognition and treatments focused on improving HRQoL.


  • Open Access

    Treatment of pruritus in primary sclerosing cholangitis: Analysis of the consortium for autoimmune liver disease registry

    by Richard Dean, Maryam Yazdanfar, Joseph Zepeda, Cynthia Levy, Craig Lammert, Daniel Pratt, Stuart C. Gordon, Lisa Forman, David N. Assis, Ashleigh McGirr, et al.

    Background: Cholestasis from primary sclerosing cholangitis (PSC) frequently causes pruritus. However, the prevalence of pruritus and its management have not been well studied. Investigating the Cholestatic Pruritus of Primary Sclerosing Cholangitis (ItCh-PSC) includes a retrospective medical record review to determine the prevalence, severity, and treatment patterns of pruritus. Methods: Data was collected at 5 academic medical centers in the United States. Medical records were searched for the terms “itch” and “pruritus” and data abstracted related to itch severity, number of encounters, and treatment. Results: Among 724 patients with PSC, 359 (50%) of patients had a documented history of pruritus, including 40%, 39%, and 21% with mild, moderate, or severe itch. Itch was less common in those with small ducts compared to large duct PSC (p=0.02) and more frequent in those of Hispanic versus non-Hispanic ethnicity (p=0.001). Compared to patients with mild itch, patients with moderate or severe itch were younger, and had more elevated liver biochemistries, more encounters with itch, and more frequently prescribed 2 or more anti-pruritic medications. Bile acid–binding resins were prescribed in 36%, hydroxyzine in 23%, rifampin in 11%, and fenofibrate in 4% of patients with any itch. The prevalence and severity of pruritus were not affected by cirrhosis, hepatic decompensation, or inflammatory bowel disease. Conclusion: Itch is common in patients with PSC and is often associated with multiple prescriptions of antipruritic agents. Effective treatments for pruritus in patients with PSC remain an unmet need.


  • Open Access

    An early look at the second dose completion of the recombinant zoster vaccine in Canadian adults: A retrospective database study

    by Ashleigh McGirr, Tara Bourgoin, Michael Wortzman, Brad Millson, Shelly A. McNeil


  • The health and economic burden of pertussis in Canada: A microsimulation study

    by Ashleigh McGirr, David N. Fisman, Ashleigh R. Tuite


  • Open Access

    Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults

    by Ashleigh McGirr, Desiree Van Oorschot, Robyn Widenmaier, Michael Stokes, Michael L. Ganz, Hyosung Jung, Lijoy Varghese, Desmond Curran

    Objectives In Canada, incidences of herpes zoster (HZ) and postherpetic neuralgia (PHN) are increasing, posing a significant burden on the healthcare system. This study aimed to determine the public health impact and cost effectiveness of an adjuvanted recombinant zoster vaccine (RZV) compared to no vaccination and to the live attenuated vaccine (ZVL) in Canadians aged 60 years and older. Methods A multi-cohort Markov model has been adapted to the Canadian context using recent demographic and epidemiologic data. Simulations consisted of age-cohorts annually transitioning between health states. Health outcomes and costs were discounted at 1.5% per year. The perspective of the Canadian healthcare payer was adopted. A coverage of 80% for the first RZV and ZVL dose and a compliance of 75% for the second RZV dose were assumed. Results RZV was estimated to be cost effective compared with no vaccination with an incremental cost-effectiveness ratio (ICER) of $28,360 (Canadian dollars) per quality-adjusted life-year (QALY) in persons aged ≥ 60 years, avoiding 554,504 HZ and 166,196 PHN cases. Compared with ZVL, RZV accrued more QALYs through the remaining lifetime and an increase in costs of approximately $50 million resulting in an average ICER of $2396. Results were robust under deterministic and probabilistic sensitivity analyses. HZ incidence rate and persistence of vaccine efficacy had the largest impact on cost effectiveness. Conclusions The cost-utility analysis suggested that RZV would be cost effective in the Canadian population compared with no vaccination and vaccination with ZVL at a willingness-to-pay threshold of $50,000.


  • Open Access

    A systematic literature review and network meta-analysis feasibility study to assess the comparative efficacy and comparative effectiveness of pneumococcal conjugate vaccines

    by Ashleigh McGirr, Shehzad M. Iqbal, Patricia Izurieta, Carla Talarico, Janneke Luijken, Josefine Redig, Rachel S. Newson

    Background: No head-to-head studies are currently available comparing pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with 13-valent pneumococcal conjugate vaccine (PCV-13). This study explored the feasibility of using network meta-analysis (NMA) to conduct an indirect comparison of the relative efficacy or effectiveness of the two vaccines. Methods: A systematic literature search was conducted for published randomized controlled trials (RCTs) and non-RCT studies reporting data on vaccine efficacy or effectiveness against invasive pneumococcal disease in children aged <5 years receiving 7-valent pneumococcal conjugate vaccine (PCV-7), PHiD-CV or PCV-13. Study quality was evaluated using published scales. NMA feasibility was assessed by considering whether a connected network could be constructed by examining published studies for differences in study or patient characteristics that could act as potential treatment effect modifiers or confounding variables. Results: A total of 26 publications were included; 2 RCTs (4 publications), 7 indirect cohort studies, and 14 case-control studies (15 publications). Study quality was generally good. The RCTs could not be connected in a network as there was no common comparator. The studies differed considerably in design, dose number, administration schedules, and subgroups analyzed. Reporting of exposure status and subject characteristics was inconsistent. Conclusion: NMA to compare the relative efficacy or effectiveness of PHiD-CV and PCV-13 is not feasible on the current evidence base, due to the absence of a connected network across the two RCTs and major heterogeneity between studies. NMA may be possible in future if sufficient RCTs become available to construct a connected network.


  • Open Access

    The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis

    by Ashleigh McGirr, Robyn Widenmaier, Desmond Curran, Emmanuelle Espié, Tomas Mrkvan, Lidia Oostvogels, Benedetto Simone, Janet E. McElhaney, Heather Burnett, Katrin Haeussler, et al.


  • Open Access

    Estimation of the Underlying Burden of Pertussis in Adolescents and Adults in Southern Ontario, Canada

    by Ashleigh A. McGirr, Ashleigh R. Tuite, David N. Fisman

    Despite highly successful vaccination programs and high vaccine uptake, both endemic pertussis and periodic pertussis outbreaks continue to occur. The under-recognized role of adolescents and adults in disease transmission, due to waning immunity following natural infection and vaccination, and reduced likelihood of correct diagnosis, may contribute to pertussis persistence. We constructed a mathematical model to describe the transmission of pertussis in Southern Ontario in both pre-vaccine and vaccine eras, to estimate the underlying burden of pertussis in the population. The model was well calibrated using the best available data on pertussis in the pre-vaccination (1880–1929) and vaccination (1993–2004) eras in Ontario. Pertussis under-reporting by age group was estimated by comparing model-projected incidence to reported laboratory-confirmed cases for Greater Toronto. Best-fit model estimates gave a basic reproductive number of approximately 10.6, (seasonal range 9.9 to 11.5). Under-reporting increased with age, and approximately >95% of infections in children were caused by infections in persons with waning immunity to pertussis following prior infection or vaccination. A well-calibrated model suggests that under-recognized cases of pertussis in older individuals are likely to be an important driver of ongoing pertussis outbreaks in children. Model projections strongly support enhancement of booster vaccination efforts in adults.